Joseph Meletiadis

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint The concentration-dependent nature of in vitro amphotericin B-itraconazole interaction against Aspergillus fumigatus: isobolographic and response surface analysis of complex pharmacodynamic interactions
    Joseph Meletiadis
    National Cancer Institute, Pediatric Oncology Branch, Bethesda, MD 20892, USA
    Int J Antimicrob Agents 28:439-49. 2006
  2. pmc Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus
    Theodouli Stergiopoulou
    Immunocompromised Host Section, Pediatric Oncology Branch, Clinical Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Antimicrob Chemother 63:343-8. 2009
  3. pmc Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology
    Joseph Meletiadis
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 51:3329-37. 2007
  4. pmc Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model
    Joseph Meletiadis
    National Cancer Institute, Pediatric Oncology Branch, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 51:2053-64. 2007
  5. pmc Isobolographic analysis of pharmacodynamic interactions between antifungal agents and ciprofloxacin against Candida albicans and Aspergillus fumigatus
    Theodouli Stergiopoulou
    Immunocompromised Host Section, Pediatric Oncology Branch, Clinical Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Antimicrob Agents Chemother 52:2196-204. 2008
  6. doi request reprint Comparative pharmacodynamic interaction analysis of triple combinations of caspofungin and voriconazole or ravuconazole with subinhibitory concentrations of amphotericin B against Aspergillus spp
    Joanne P Demchok
    Immunocompromised Host Section, National Cancer Institute, Bethesda, MD 20892 1928, USA
    Mycoses 53:239-45. 2010
  7. pmc Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia
    Charalampos Antachopoulos
    Pediatric Oncology Branch, National Cancer Institute, CRC, Rm 1 5750, MSC 1100, 10 Center Drive, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 52:321-8. 2008
  8. pmc Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis
    Vidmantas Petraitis
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Building 10, Rm 1W 5750, 10 Center Drive, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 53:2382-91. 2009
  9. ncbi request reprint Use of high inoculum for early metabolic signalling and rapid susceptibility testing of Aspergillus species
    Charalampos Antachopoulos
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Antimicrob Chemother 59:230-7. 2007
  10. ncbi request reprint Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species
    Elizabeth M O'Shaughnessy
    Immunocompromised Host Section, Pediatric Oncology Branch, Clinical Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Antimicrob Chemother 58:1168-76. 2006

Collaborators

Detail Information

Publications26

  1. ncbi request reprint The concentration-dependent nature of in vitro amphotericin B-itraconazole interaction against Aspergillus fumigatus: isobolographic and response surface analysis of complex pharmacodynamic interactions
    Joseph Meletiadis
    National Cancer Institute, Pediatric Oncology Branch, Bethesda, MD 20892, USA
    Int J Antimicrob Agents 28:439-49. 2006
    ..5 mg/L). Synergy was more frequently observed for the itraconazole-resistant isolates than for the itraconazole-susceptible isolates...
  2. pmc Comparative pharmacodynamic interaction analysis between ciprofloxacin, moxifloxacin and levofloxacin and antifungal agents against Candida albicans and Aspergillus fumigatus
    Theodouli Stergiopoulou
    Immunocompromised Host Section, Pediatric Oncology Branch, Clinical Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Antimicrob Chemother 63:343-8. 2009
    ..However, little is known about the interaction between other extended-spectrum fluoroquinolones, such as levofloxacin and moxifloxacin, and antifungal agents against C. albicans and A. fumigatus...
  3. pmc Differential fungicidal activities of amphotericin B and voriconazole against Aspergillus species determined by microbroth methodology
    Joseph Meletiadis
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 51:3329-37. 2007
    ....
  4. pmc Concentration-dependent synergy and antagonism within a triple antifungal drug combination against Aspergillus species: analysis by a new response surface model
    Joseph Meletiadis
    National Cancer Institute, Pediatric Oncology Branch, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 51:2053-64. 2007
    ..In conclusion, the new nonlinear mixture-amount response surface modeling of the triple antifungal combination demonstrated a net antagonism or synergy against Aspergillus species depending upon drug concentrations and species...
  5. pmc Isobolographic analysis of pharmacodynamic interactions between antifungal agents and ciprofloxacin against Candida albicans and Aspergillus fumigatus
    Theodouli Stergiopoulou
    Immunocompromised Host Section, Pediatric Oncology Branch, Clinical Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892, USA
    Antimicrob Agents Chemother 52:2196-204. 2008
    ..fumigatus. Isobolographic analysis may help to elucidate the pharmacodynamic interactions between antifungal and non-antifungal agents and to develop better management strategies against invasive candidiasis and aspergillosis...
  6. doi request reprint Comparative pharmacodynamic interaction analysis of triple combinations of caspofungin and voriconazole or ravuconazole with subinhibitory concentrations of amphotericin B against Aspergillus spp
    Joanne P Demchok
    Immunocompromised Host Section, National Cancer Institute, Bethesda, MD 20892 1928, USA
    Mycoses 53:239-45. 2010
    ..fumigatus and A. flavus, while it increased the synergy against A. terreus...
  7. pmc Comparative in vitro pharmacodynamics of caspofungin, micafungin, and anidulafungin against germinated and nongerminated Aspergillus conidia
    Charalampos Antachopoulos
    Pediatric Oncology Branch, National Cancer Institute, CRC, Rm 1 5750, MSC 1100, 10 Center Drive, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 52:321-8. 2008
    ..The paradoxical increase in metabolism occurred more frequently and at lower concentrations with caspofungin than with micafungin and anidulafungin...
  8. pmc Combination therapy in treatment of experimental pulmonary aspergillosis: in vitro and in vivo correlations of the concentration- and dose- dependent interactions between anidulafungin and voriconazole by Bliss independence drug interaction analysis
    Vidmantas Petraitis
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Building 10, Rm 1W 5750, 10 Center Drive, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 53:2382-91. 2009
    ....
  9. ncbi request reprint Use of high inoculum for early metabolic signalling and rapid susceptibility testing of Aspergillus species
    Charalampos Antachopoulos
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Antimicrob Chemother 59:230-7. 2007
    ..To develop and evaluate a new method for rapid susceptibility testing of Aspergillus spp. based on early metabolic signalling of high-inoculum biomass...
  10. ncbi request reprint Antifungal interactions within the triple combination of amphotericin B, caspofungin and voriconazole against Aspergillus species
    Elizabeth M O'Shaughnessy
    Immunocompromised Host Section, Pediatric Oncology Branch, Clinical Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA
    J Antimicrob Chemother 58:1168-76. 2006
    ..The in vitro effects of caspofungin combined with voriconazole and amphotericin B were tested in triplicate experiments against nine clinical isolates of Aspergillus fumigatus, Aspergillus flavus and Aspergillus terreus...
  11. pmc Concentration-dependent effects of caspofungin on the metabolic activity of Aspergillus species
    Charalampos Antachopoulos
    Pediatric Oncology Branch, National Cancer Institute, 10 Center Drive, Bethesda, MD 20892, USA
    Antimicrob Agents Chemother 51:881-7. 2007
    ..Assessment of metabolic activity may provide useful quantitative endpoints for in vitro studies of caspofungin against Aspergillus spp...
  12. doi request reprint In vitro activity of CAY-1, a saponin from Capsicum frutescens, against Microsporum and Trichophyton species
    Theodouli Stergiopoulou
    Pediatric Oncology Branch, National Cancer Institute, NIH, Bethesda, MD 20892, USA
    Med Mycol 46:805-10. 2008
    ..Results indicate that CAY-1 merits further investigation as a potential agent for the treatment of dermatomycoses...
  13. ncbi request reprint Host-dependent patterns of tissue injury in invasive pulmonary aspergillosis
    Theodouli Stergiopoulou
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    Am J Clin Pathol 127:349-55. 2007
    ..Thus, the status of innate host defenses contributes significantly to the histologic patterns observed in IPA...
  14. doi request reprint Defining targets for investigating the pharmacogenomics of adverse drug reactions to antifungal agents
    Joseph Meletiadis
    National Cancer Institute, National Institutes of Health, Pediatric Oncology Branch, Bethesda, MD 20814, USA
    Pharmacogenomics 9:561-84. 2008
    ....
  15. pmc Infections caused by Scedosporium spp
    Karoll J Cortez
    Immunocompromised Host Section, Pediatric Oncology Branch, National Cancer Institute, Bethesda, Maryland, USA
    Clin Microbiol Rev 21:157-97. 2008
    ..By comparison, infections caused by S. prolificans seldom respond to medical therapy alone. Surgery and reversal of immunosuppression may be the only effective therapeutic options for infections caused by S. prolificans...
  16. ncbi request reprint Study of common functional genetic polymorphisms of FCGR2A, 3A and 3B genes and the risk for cryptococcosis in HIV-uninfected patients
    Joseph Meletiadis
    National Cancer Institute, Bethesda, MD, USA
    Med Mycol 45:513-8. 2007
    ..40% in controls). An analysis of haplotypes showed a significant difference in distribution between cases and controls overall and in Caucasians...
  17. ncbi request reprint Triazole-polyene antagonism in experimental invasive pulmonary aspergillosis: in vitro and in vivo correlation
    Joseph Meletiadis
    Immunocompromised Host Section, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    J Infect Dis 194:1008-18. 2006
    ..No pharmacokinetic interaction was found. The combination of a triazole and polyene may be antagonistic in the treatment of invasive pulmonary aspergillosis...
  18. pmc Human pharmacogenomic variations and their implications for antifungal efficacy
    Joseph Meletiadis
    Pediatric Oncology Branch, National Cancer Institute, CRC, 1 5750 10 Center Drive, Bethesda, MD 20892, USA
    Clin Microbiol Rev 19:763-87. 2006
    ..Pharmacogenomics has the potential to shift the paradigm of therapy and to improve the selection of antifungal compounds and adjustment of dosage based upon individual variations in drug absorption, metabolism, and excretion...
  19. pmc Rapid susceptibility testing of medically important zygomycetes by XTT assay
    Charalampos Antachopoulos
    Pediatric Oncology Branch, National Cancer Institute, CRC, Rm 1 5750, MSC 1100, 10 Center Drive, Bethesda, MD 20892, USA
    J Clin Microbiol 44:553-60. 2006
    ..These results support the use of the XTT method for rapid MIC determination for Zygomycetes...
  20. ncbi request reprint Susceptibility testing of sequential isolates of Aspergillus fumigatus recovered from treated patients
    Eric Dannaoui
    Laboratoire de Parasitologie, Mycologie Medicale et Pathologie Exotique, Universite Claude Bernard Lyon I, 69373 Lyon Cedex 08, France
    J Med Microbiol 53:129-34. 2004
    ..It is concluded that the emergence of resistance in A. fumigatus during antifungal therapy with amphotericin B or itraconazole is an uncommon phenomenon...
  21. ncbi request reprint Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models
    Joseph Meletiadis
    Department of Medical Microbiology, Nijmegen University Center for Infectious Diseases, Nijmegen, The Netherlands
    Med Mycol 43:133-52. 2005
    ..Semi-parametric approaches need particular care as experimental errors are not eliminated from the entire response surface...
  22. pmc Comparison of the Etest and the sensititre colorimetric methods with the NCCLS proposed standard for antifungal susceptibility testing of Aspergillus species
    Joseph Meletiadis
    Department of Medical Microbiology, University Medical Center Nijmegen, The Netherlands
    J Clin Microbiol 40:2876-85. 2002
    ....
  23. pmc Use of turbidimetric growth curves for early determination of antifungal drug resistance of filamentous fungi
    Joseph Meletiadis
    Department of Medical Microbiology, University Medical Center Nijmegen, Nijmegen, The Netherlands
    J Clin Microbiol 41:4718-25. 2003
    ..8 to 11.4 h for A. fumigatus, 6.7 to 8.5 h for A. flavus, and 13 to 15.6 h for S. prolificans while awaiting formal MIC determination by the NCCLS reference method...
  24. pmc In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates
    Joseph Meletiadis
    Department of Medical Microbiology, University Medical Center Nijmegen, Nijmegen, The Netherlands
    Antimicrob Agents Chemother 47:106-17. 2003
    ..Fully parametric approaches in combination with the modified colorimetric method might prove useful for testing the in vitro interaction of antifungal drugs against filamentous fungi...
  25. ncbi request reprint In vitro susceptibilities of zygomycetes to conventional and new antifungals
    Eric Dannaoui
    Department of Medical Microbiology, University Medical Center, St Radboud, PO Box 9101, 6500 HB Nijmegen
    J Antimicrob Chemother 51:45-52. 2003
    ..The spectrophotometric method appears to be a valuable alternative to the visual method for MIC determination for zygomycetes...
  26. pmc In vitro activities of new and conventional antifungal agents against clinical Scedosporium isolates
    Joseph Meletiadis
    Departments of Medical Microbiology, University Medical Center, Nijmegen, The Netherlands
    Antimicrob Agents Chemother 46:62-8. 2002
    ..These cutoffs were in many cases reproducible between 48 and 72 h...